Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417776 · ClinicalTrials.gov registry record · Phase 2
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
A Phase 2 study of Interstitial Lung Disease, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05417776: Recruiting Phase 2 study of Interstitial Lung Disease, sponsored by Massachusetts General Hospital.
NCT05417776 is a Phase 2 study of Interstitial Lung Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05417776, a Phase 2 study of Interstitial Lung Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.
Primary Outcome
The degree of uptake of \[68Ga\]CBP8 in the lungs will be compared between groups and associations with disease severity and progression will be determined.
Conditions Studied
Interventions
- DRUG [68Ga]CBP8
- DRUG Dotarem
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 2 |
What NCT05417776 shows while recruiting
NCT05417776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Interstitial Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which [68Ga]CBP8 is the first listed.
NCT05417776 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05417776 about?
NCT05417776 is a clinical study titled "Collagen-targeted PET Imaging for Early Interstitial Lung Disease". The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.
What is the current status of trial NCT05417776?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-09-28. Estimated completion is 2026-04-01.
What conditions does trial NCT05417776 study?
This clinical trial studies the following conditions: Interstitial Lung Disease.
What interventions are being tested in trial NCT05417776?
The interventions under investigation include: [68Ga]CBP8 (DRUG), Dotarem (DRUG).
Who is sponsoring clinical trial NCT05417776?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05417776 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05417776's enrollment target sits among peer trials
30 27th of 36 higher than 7 of 36 other Interstitial Lung Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Lung Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI